Clinical Advisory Board

György Bodoky, MD. Ph.D.

Dr. Bodoky is the Head of the Oncology Department at Szent László Teaching Hospital in Budapest, Hungary.

 

Dr. Bodoky has conducted his investigations about the enteral and parenteral nutrition, the special research interests in this area have included the nutrition in pancreas disease, in liver coma and malignant diseases. The second area of his research includes the organization of Hungarian activities in clinical trials for gastrointestinal oncology, he has been and/or currently is the principal investigator in 132 studies, has been organizing 22 international conferences in the field of oncology and co-authored a number of peer-reviewed publications and textbooks both internationally and nationally.

Dr Bodoky is a member of the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the European Society for Parenteral and Enteral Nutrition (ESPEN). He is the Honorary President of the Hungarian Society of Clinical Oncology (HSCO). He is also a member of the Swiss Group for Clinical Cancer Research (SAKK) and a founding member of South-Eastern European Research Oncology Group (SEEROG). He was invited to be a member of the ARCAD Foundation (Academic Research on Cancer for Answers and Directions)

 

He is the chief editor “Journal of Clinical Oncology” (Hungarian edition) and a board member of the journal ”Journal of Metabolism and Nutrition” and founding editor of the journal “Rákgyógyítás”.

 

He received his medical degree from the Semmelweis Medical University Budapest, subsequently he obtained his PhD in 1992 and his Habilitation in 1998 from the Semmelweis Medical University.

David Feigal, M.D.

Dr. Feigal is a Partner in NDA Partners. He spent 12 years with the US Food & Drug Administration (FDA) where he was Director, Center for Devices & Radiological Health (CDRH), Director, Division of Anti-infective & Antiviral Drug Products, Center for Drug Evaluation & Research (CDER), and Deputy Director, Center for Biologics Evaluation & Research (CBER).  He is former Vice President of Global Regulatory Strategy, Amgen, and former Senior Vice President, Head of Global Regulatory and Global Safety Surveillance at Elan Corporation.  Dr Feigal has more than 30 years of experience in drug development and regulation.  Before joining the FDA, he worked for 10 years within the academic and hospital settings of the University of California in San Diego, San Francisco, and Davis.

 

He holds a BA from University of Minnesota, an MD from Stanford University and a Master of Public Health from the University of California, Berkeley.

Axel Grothey, M.D.

Dr. Grothey is a consultant in the Division of Medical Oncology, Department of Oncology, at Mayo Clinic. He holds the academic rank of professor of oncology and has teaching/examining privileges in Clinical & Translational Science at Mayo Graduate School. He is a member of Mayo Clinic’s Cancer Center.

 

Dr. Grothey’s clinical interests focus on gastrointestinal cancers, in particular, colorectal cancer, anti-angiogenesis, signal transduction inhibitors, and clinical trial design and statistics. As a consultant and investigator, his research has been funded by the National Cancer Institute (NCI) and the National Institutes of Health, among other organizations. He currently chairs the NCI colon cancer task force, and serves as member of the gastrointestinal cancer steering committee of the Alliance for Clinical Trials in Oncology, an NCI-funded cooperative group. He is also chair of the Academic and Community Cancer Research United (ACCRU) international research network. He currently holds professional positions in the Association of German Internists, German Cancer Association, Working Group of Experimental Cancer Research in Germany, American Association for Cancer Research, European Association for Cancer Research, American Society for Cell Biology, MD Anderson Associates, American Society of Clinical Oncology, European Society for Medical Oncology, German Association for Internal Oncology and the Minnesota Medical Association. He also has served in various leadership positions at Mayo Clinic Cancer Center. From 2014 to 2016 he was President of the International Society of Gastrointestinal Oncology (ISGIO).

 

He serves in journal review and editorial activities for numerous medical journals and is editor for Clinical Colorectal Cancer, Emerging Cancer Therapeutics, PracticeUpdate Oncology, and Therapeutic Advances in Medical Oncology. He has co-authored more than 500 articles, books, book chapters, editorials, abstracts and letters.

 

He received his medical degree at Ruhr-Universität Bochum, Germany, and completed a residency and fellowship at the University of Bochum as well as a research fellowship at MD Cancer Center at the University of Texas.

Pamela M. Klein, M.D.
Dr. Klein is Principal of PMK BioResearch offering advisory and strategic consulting for biotechnology and the pharmaceutical industry with deep expertise in oncology drug development. She serves as an advisor to Corporate Boards, CEO’s, The Investment Community and Management Teams. She is on the Board of Directors for Argenx (Netherlands) and an active member of numerous Scientific Advisor Boards ranging from early start-ups to more established companies. Previously, she was Chief

Medical Officer of Intellikine (acquired by Milleinium/Takeda), where she built the development organization bringing multiple early compounds from laboratory to clinic. Prior to this, Klein was Vice President, Development at Genentech where she led the development of a large portfolio of drugs including all the HER (Herceptin, Tarceva, Perjeta), Apoptosis (antibodies and small molecules) and Hematology compounds. Prior to Genentech, she was at The National Cancer Institute, where she obtained funding, built and served as Research Director of the NCI-Navy Breast Center.

 

She received her medical degree from Stritch School of Medicine, Loyola, completed a Medical Oncology Fellowship at the NCI serving as Chief Fellow and then completed an additional year in Cancer Genetics.

Peter Wagner, M.D.

Dr. Wagner is a member of the Kalispell Regional Medical Center medical staff and the practice of Northwest Oncology and Hematology.

 

Before heading for the Flathead Valley, he was a medical oncologist at High Plains Oncology in Pueblo, Colorado. Dr. Wagner treats patients with a wide variety of cancer diagnoses, and has a deep understanding of the emotional toll that the disease can take on all affected. He gained a great deal of experience working with patients under stress in the Hurricane Katrina aftermath, when he found himself with nearly 20 cancer patients who could not leave the hospital for quite some time. Not only were they dealing with the stress of cancer, but the fears and anxiety caused by the natural disaster. “That experience taught me a lot about people and how they handle stress,” he said. “I had to make a lot of tough decisions under very tough circumstances. In the end I learned that life’s stresses can bring out the best in some people.” In his free time, Dr. Wagner is a dedicated skier and mountain biker who is eager to explore Flathead Valley trails.

 

He received his medical degree from Szent-Gyorgyi Albert Medical University in Szeged, Hungary, served as a postdoctoral research fellow in the Breast Medical Oncology Department at MD Anderson Cancer Center in Texas and completed a fellowship in medical oncology at Ochsner Clinic Foundation Hospital in New Orleans, Louisiana.